NewTimeSpace News:As of 09:45 on February 5, 2026, the CSI All-Cap Medical Device Index (H30217) rose 0.14%. Among its constituent stocks, Aesthetic Medical International Holdings Group Co., Ltd. rose 4.36%, Hansoh Pharmaceutical Group Co., Ltd. climbed 2.71%, Cobetter Medical Technology Co., Ltd. advanced 2.26%, Jinbo Biotechnology Co., Ltd. increased by 1.99%, and Sinocare Co., Ltd. gained 1.89%. The Maxwealth CSI All Share Medical Apparatus And Instruments ETF (159883) rose 0.39%, approaching a three-day winning streak, with the latest price at RMB 0.51. Over a longer time frame, as of February 4, 2026, the ETF had achieved a cumulative increase of 5.13% in the past month. (The stocks listed above are merely constituent stocks of the index and do not constitute specific investment recommendations.)

In terms of liquidity, the Maxwealth CSI All Share Medical Apparatus And Instruments ETF recorded an intraday turnover rate of 0.57% and a trading volume of RMB 37.7799 million. Looking back, as of February 4, the ETF's average daily trading volume in the past month reached RMB 382 million, ranking first among comparable funds.

Regarding scale, the latest size of the Maxwealth CSI All Share Medical Apparatus And Instruments ETF stood at RMB 6.65 billion, a new high in nearly one year, ranking 1st out of 4 comparable funds. (Data source: Wind)

In terms of share count, the latest share of the Maxwealth CSI All Share Medical Apparatus And Instruments ETF reached 12.96 billion units, a new high in nearly one year, ranking 1st out of 4 comparable funds. (Data source: Wind)

For capital inflows, the Maxwealth CSI All Share Medical Apparatus And Instruments ETF recorded a latest net capital inflow of RMB 170 million. Over the recent 5 trading days, it achieved net capital inflows on 4 days, accumulating a total of RMB 219 million in "capital absorption" and an average daily net inflow of RMB 43.8499 million. (Data source: Wind)

Data shows that leveraged capital has been continuously deploying in the ETF. The latest margin purchase amount of the Maxwealth CSI All Share Medical Apparatus And Instruments ETF reached RMB 26.8735 million, and the latest margin trading balance stood at RMB 275 million. (Data source: Wind)

As of February 4, the Maxwealth CSI All Share Medical Apparatus And Instruments ETF had a NAV increase of 10.63% in the past year. In terms of profitability, as of February 4, 2026, since its establishment, the ETF has achieved a maximum monthly return of 22.97%, the longest consecutive monthly growth period of 4 months with a cumulative increase of 19.79%, and an average monthly return of 4.73% in upward months. As of February 4, 2026, the ETF's annualized excess return over the benchmark in the past two years was 1.10%, ranking among the top 2 out of 4 comparable funds.

Regarding drawdown, as of February 4, 2026, the ETF's maximum drawdown since the beginning of the year was 9.63%, with a relative benchmark drawdown of 0.11%.

In terms of fees, the Maxwealth CSI All Share Medical Apparatus And Instruments ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%, which are at a relatively low level among comparable funds.

For tracking accuracy, as of February 4, 2026, the ETF's tracking error in the past six months was 0.018%, the highest tracking accuracy among comparable funds.

Notably, the valuation of the CSI All-Cap Medical Device Index tracked by the fund is at a historical low. The latest price-to-book ratio (PB) is 3.09 times, lower than 81.96% of the time in the past five years, highlighting prominent valuation cost-effectiveness.

The Maxwealth CSI All Share Medical Apparatus And Instruments ETF closely tracks the CSI All-Cap Medical Device Index. To reflect the overall performance of listed company securities in different industries within the CSI All-Cap Index sample and provide analytical tools for investors, the CSI All-Cap Index sample is classified into 11 primary industries, 35 secondary industries, more than 90 tertiary industries, and over 200 quaternary industries according to the CSI Industry Classification. Indices are then compiled using all securities in each primary, secondary, tertiary, and quaternary industry as samples, forming the CSI All-Cap Industry Indices.

Data shows that as of January 30, 2026, the top 10 weight stocks of the CSI All-Cap Medical Device Index (H30217) were Mindray Medical International Limited, United Imaging Healthcare Co., Ltd., Yuyue Medical Equipment & Supply Co., Ltd., Lepu Medical Technology (Beijing) Co., Ltd., Neusoft Medical Systems Co., Ltd., Aesthetic Medical International Holdings Group Co., Ltd., Huida Medical Co., Ltd., Intco Medical Technology Co., Ltd., Furui Medical Co., Ltd., and Yiree Technology Co., Ltd., with a combined weight of 43.63%. (The stocks listed above are merely constituent stocks of the index and do not constitute specific investment recommendations.)

CITIC SECURITIES CO.,LTD. stated that the National Healthcare Security Administration (NHSA) has issued a new policy, formulating guidelines for the pricing and project approval of services related to surgical robots and surgical consumables. The promotion and popularization of surgical robots in China are expected to accelerate. Meanwhile, the NHSA indicated that the project approval guidelines will continue to expand in the future, benefiting the overall innovative medical device products.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.